

ReLASV® Pan-Lassa Prefusion GP IgM ELISA Kit

(Human anti-LASV Prefusion GP Antibody)

For Research Use Only

Not for use in diagnostic procedures.
The performance characteristics of this product have not been established.

INSTRUCTIONS FOR USE

PRINCIPLE OF THE TEST

Lassa fever (LF) is a severe, often fatal, febrile illness endemic to West Africa caused by Lassa virus (LASV; family Arenaviridae)(1-4). LASV encodes four major proteins, including the envelope glycoproteins (GP1 and GP2), the structural protein Z, and the nucleoprotein (NP). Advanced protein chemistry techniques have been used to develop non-infectious, recombinant LASV GP antigen(5) which is stabilized in the prefusion conformation to enhance detection of LASV neutralizing antibodies(6). The ELISA test utilizes a mixture of LASV Prefusion GP antigen from the three most prevalent lineages of LASV (lineage II, III in Nigeria, lineage IV in Sierra Leone, Guinea, and Liberia) to provide Pan-Lassa cross-reactivity(7). The family of ReLASV Pan-Lassa antigen and antibody products has demonstrated capacity to detect LASV antigen and LASV-specific IgG or IgM antibody in active LF cases and LF survivors (8-13).

This Enzyme-linked Immunosorbent Assay (ELISA) detects human IgM antibody specific for LASV GP antigens. Diluted plasma or serum samples, Calibrator, Positive Control, and Negative Control are incubated in microwells coated with recombinant LASV Prefusion GP antigens. Incubation allows the LASV-specific antibodies present in the samples to react with the immobilized antigen mixture. After the removal of unbound plasma or serum proteins with the PBS-Tween wash, the anti-human IgM - horseradish peroxidase (HRP) conjugate reagent is added to bind with the absorbed LASV-specific IgM antibody. Following another washing step, the bound enzyme-antibody conjugate is assayed by the addition of TMB substrate. Color develops in the wells at an intensity proportional to the concentration of the LASV-specific IgM antibody in the sample. Substrate color development is stopped by addition of the ELISA Stop Solution.

Optical Density (O.D.) results are obtained by reading the absorbance at 450 nm (minus 620 – 650 nm reference) using an ELISA plate reader. It is recommended that the user establish a cut-off for the study population using LASV sero-negative samples. It is also recommended that a well characterized, IgM positive, convalescent LF sample from the study population be included in each assay as an additional reference sample.

REAGENTS

Store at 2–8°C. Do Not Freeze. Each kit contains the following reagents:

Component	2-plate kit (10144)	10-plate kit (10144-10)
Prefusion GP Antigen Coated Microwell Plate (resealable bag with desiccant)	Two 12x8 plates	Ten 12x8 plates
Anti-Hu IgM HRP Conjugate Solution (Blue)	1 x 25 mL bottle	1 x 120 mL bottle
GP IgM Calibrator (recombinant human MAb in human plasma, lyophilized)	2 x 0.25 mL vials	10 x 0.25 mL vials
IgM Positive Control (recombinant human MAb in human plasma, lyophilized)	2 x 0.25 mL vials	10 x 0.25 mL vials
Negative Control (human plasma, lyophilized)	2 x 0.25 mL vials	10 x 0.25 mL vials
Sample Diluent 2	1 x 120 mL bottle	3 x 250 mL bottles
ELISA Wash Concentrate (33X PBS/Tween 20)	1 x 120 mL bottle	2 x 120 mL bottles
ELISA One-Component Substrate (TMB and H ₂ O ₂); ready to use. (Amber Bottle)	1 x 25 mL bottle	1 x 120 mL bottle
ELISA Stop Solution (2% methanesulfonic acid) (Red Cap)	1 x 25 mL bottle	1 x 120 mL bottle

WARNINGS AND PRECAUTIONS

For Research Use Only. Not for use in diagnostic procedures.

Lassa Virus is classified as NIAID Category A agent. Handling of infectious blood and serum requires advanced biocontainment (BSL-4) facilities. Use of this product in BSL -1, -2 or -3 facilities is not recommended. If advanced biocontainment facilities are not available, the use of all possible universal precautions is highly recommended including face shields, masks or respiratory equipment, disposable gowning, and gloves. Decontamination equipment and solutions should be readily available. Biohazardous wastes should be autoclaved and/or incinerated.

1. Human source material used to prepare the controls included in this kit has been tested and shown to be nonreactive for hepatitis B surface antigen, negative for antibodies to HIV, and negative for HCV. However, all human blood derivatives, including patient samples, should be handled as potentially infectious material (Universal Precautions).

Biological Risk. 

2. Do not pipette by mouth.
3. Do not smoke, eat, or drink in areas where kit reagents, samples, or assay wastes are handled.
4. When testing in facilities with limited biocontainment equipment, wear personal protective equipment (PPE) including disposable gloves, face shields, N95 masks, and gowning while handling samples and assay wastes. Dispose PPE in biohazard waste containers after use and wash hands thoroughly. If rubber boots are used, decontaminate with bleach solution after use.
5. One-component substrate can cause irritation to the eyes and skin. Absorption through the skin is possible. Use gloves when handling substrate and wash thoroughly after handling. Avoid mixing with oxidizing agents.
6. Certain components are labeled with the following: Irritating to eyes (R 36). Avoid contact with skin and eyes (S 24/25). In case of contact with eyes, rinse immediately with plenty of water and seek medical advice (S 26). If swallowed, seek medical advice immediately and show container or label (S 46).

Irritant. 

SAMPLE COLLECTION AND PREPARATION

Plasma or serum are the preferred sample matrices. If plasma (EDTA) is to be used, blood should be collected by venipuncture and the plasma separated from the cells immediately by centrifugation following the blood tube manufacturers recommendations. The plasma (supernatant) must be carefully removed after centrifugation to avoid contamination with platelets. Repeating the centrifugation and separation steps may be advisable to minimize platelet contamination. If not tested immediately, samples should be stored at 2–8°C. If samples are to be stored for more than 72 hours, they should be frozen at -20°C or below. Avoid repeated freezing and thawing.

If serum is to be used, the blood should be collected by venipuncture, and the serum separated from the cells by centrifugation after clot formation, following the blood tube manufacturers recommendations. If not tested immediately, serum samples should be stored as described for plasma.

Do not use grossly hemolyzed, icteric, or lipemic plasma (or serum) as these conditions may cause aberrant results. Samples containing visible particulate matter should be clarified by centrifugation before testing.

INSTRUCTIONS FOR USE

MATERIALS PROVIDED:

ReLASV® Pan-Lassa Prefusion GP IgM ELISA Kit; see “Reagents,” for a complete listing.

MATERIALS REQUIRED BUT NOT PROVIDED:

- PPE – refer to Warnings and Precautions Section
- Laboratory grade water
- Graduated cylinders
- Precision pipettors capable of delivering between 10 µL and 1000 µL, with appropriate tips
- Sample dilution tubes or deep-well sample dilution plates
- Reagent reservoirs
- Miscellaneous glassware appropriate for small volume handling
- Flask or bottle, 1 liter
- Plate reading spectrophotometer capable of reading absorbance at 450 nm (with a 620 – 650 nm reference if available).
- Multichannel pipettors capable of delivering to 8 or 12 wells simultaneously

PROCEDURAL NOTES

1. Bring samples and kit reagents to ambient temperature (18–30°C) and mix well before using; avoid foaming. Return all unused samples and reagents to refrigerated storage as soon as possible.
2. The plate reader should be programmed for reagent blank subtraction.
3. Good washing technique is critical for optimal performance of the assay. An automated microtiter plate washing system should be used with bleach added to the waste reservoir.
4. **IMPORTANT:** Failure to adequately remove residual Wash Solution can cause inconsistent color development of the Substrate Solution.
5. Use a multichannel pipettor capable of delivering to 8 or 12 wells simultaneously when possible. This speeds the process and provides more uniform incubation and reaction times for all wells.
6. Carefully controlled timing of all steps is critical. All calibrator dilutions, controls, and samples must be added within a five-minute period.
7. For all incubations, the start of the incubation period begins with the completion of reagent or sample addition.
9. Addition of all samples and reagents should be performed at the same rate and in the same sequence.
10. Incubation temperatures above or below ambient temperature (18–30°C) may contribute to inaccurate results.
11. Avoid contamination of reagents.
12. Do not use kit components beyond expiration date.
13. Do not use components from different kit lot numbers.

REAGENT PREPARATION

1X ELISA Wash Solution: Measure 30 mL of Wash Concentrate (33X) and dilute to 1 liter with laboratory grade water. Store unused Wash Solution in the refrigerator at 2–8°C . Discard if the solution shows signs of microbial contamination.

Lyophilized Controls: Reconstitute IgM Calibrator, IgM Positive Control, and Negative Control with 0.250mL laboratory grade water. Mix gently for several minutes until completely dissolved. Unused portion should be stored at 2-8°C for up to 7 days or stored frozen (-20°C or less) for longer periods.

ASSAY PROCEDURE

Note: Duplicate well testing of all Calibrator dilutions, Positive Control, Negative Control, Reagent Blank, and samples is recommended.

1. Remove any microwell strips that will not be used from the frame and store them in the re-sealable bag provided.
2. Prepare a five-point GP IgM Calibrator curve: Label five tubes for Calibrator 1 – 5.

In tube #1, prepare a 1:101 dilution of Calibrator in Sample Diluent 2 (green) by adding 10 µL Calibrator to 1000 µL Sample Diluent 2.

Add 500 µL of Sample Diluent 2 to tubes # 2-5.

Remove 250 µL from dilution tube #1, transfer to dilution tube #2 and mix well.

Repeat this 3-fold serial dilution series through tube 5.

The value of the Calibrator is indicated on the vial label. The value of Calibrator dilutions 2 - 5 are calculated by dividing Calibrator value by each Calibrator dilution factor (DF).

Example:

Dilution #	DF	Volume to Add		Sample Diluent Volume		Calibrator Value
1	-	10 µL Calibrator	+	1000 µL	=	100 µg/mL
2	3	250 µL Dilution #1	+	500 µL	=	33.3 µg/mL
3	9	250 µL Dilution #2	+	500 µL	=	11.1 µg/mL
4	27	250 µL Dilution #3	+	500 µL	=	3.7 µg/mL
5	81	250 µL Dilution #4	+	500 µL	=	1.23 µg/mL

3. A Reagent Blank control must be run in each plate. These wells are then treated the same as sample wells in subsequent assay steps.
4. Prepare a 1:101 dilution of the Positive Control, Negative Control, and samples in Sample Diluent 2; e.g., 10 µL sample added to 1000 µL Sample Diluent 2 equals a 1:101 sample dilution.
5. Add 100 µL of the prepared Calibrator dilutions, Positive Control, Negative Control, Reagent Blank, and samples to the appropriate microwells.
6. Incubate 30 minutes at ambient temperature (18-30°C).
7. After the incubation is complete, wash 4 times (300µL/well) with wash solution. Blot on absorbent paper to remove residual wash fluid. Do not allow the wells to dry out.
8. Add 100 µL of the Anti-Hu IgM HRP Conjugate Solution to each well.
9. Incubate for 30 minutes at ambient temperature (18-30°C).
10. Wash 4 x 300 µL/well with wash solution as in step 7. Blot on absorbent paper to remove residual wash fluid. Do not allow the wells to dry out.
11. Add 100 µL of the One-Component Substrate to each well and incubate for 10 minutes at ambient temperature (18-30°C) while protected from light. Blue color will develop in wells with positive samples.
12. Add 100 µL of the Stop Solution (2% methanesulfonic acid) to each well to stop the substrate color development. Blue substrate will turn yellow and colorless substrate will remain colorless.
13. The plate reader should be programmed to blank (or zero) the reader against the duplicate Reagent Blanks. Read the OD (i.e., absorbance) of each well at 450 nm (with 620 – 650 nm reference, if available). The O.D. values should be measured within 5 minutes after the addition of Stop Solution.

RESULTS

1. Calculate the mean O.D. values for the duplicates of the Calibrator dilutions, Positive Control, Negative Control, and samples. Subtract mean O.D. 620 – 650 nm reference from mean O.D. 450 nm.
2. Estimate the concentration of IgM by plotting the mean O.D. obtained for each dilution of the IgM Calibrator (y axis) against the corresponding IgM Calibrator value (x axis) using curve fitting software. A 4-Parameter curve fit calculation is recommended.
3. Ensure that all quality control parameters have been met (see Quality Control) before reporting results.
4. A new Calibrator curve should be prepared with every assay.

QUALITY CONTROL

1. The mean O.D. of the reagent blank should be less than 0.150. Readings greater than 0.150 may indicate possible reagent contamination or inadequate plate washing.
2. O.D. values for duplicates of the controls or patient samples should be within 25% CV of the mean O.D. value, for samples with O.D. readings greater than 0.250.
3. The average IgM concentration of the Positive Control recovered against the Calibrator Curve should be within the range given on the vial label.
4. Each laboratory should determine their own normal range for the appropriate population.

NORMAL CUT-OFF

To be determined experimentally by the end user within a study population. Cut-off range has not been established by manufacturer.

LIMITATIONS OF THE TEST – FOR RESEARCH USE ONLY – NOT FOR USE IN DIAGNOSTIC PROCEDURES

LASV-specific IgM antibody concentrations obtained with this assay are not for use in diagnostic procedures.

Strain variability of Old-World Arenaviruses or LCMV may affect performance of the assay.

The presence of Rheumatoid Factor (RF) in LF samples may interfere with ELISA methods by binding to antibodies. The presence of RF should be considered when evaluating results.









Testing LF samples containing excess hemoglobin, lipids, and/or bilirubin is not recommended as these substances may interfere with the results of the assay.

The performance characteristics of this assay have not been established.

REFERENCES

1. J. G. Shaffer *et al.*, Lassa Fever in Post-Conflict Sierra Leone. *PLoS Negl Trop Dis* **8**, e2748 (2014), PMID: 24651047.
2. D. A. Asogun *et al.*, Lassa Fever: Epidemiology, Clinical Features, Diagnosis, Management, and Prevention. *Infect Dis Clin North Am* **33** (4): 933-51 (2019), PMID: 31668199.
3. N. Sogoba *et al.*, Lassa Fever in West Africa: Evidence for expanded region of Endemicity. *Zoonoses and Public Health* **59** (Suppl. 2), 43-7 (2012), PMID: 22958249.
4. A. Q. N. Mylne *et al.*, Mapping the zoonotic niche of Lassa fever in Africa. *Trans R Soc Trop Med Hyg* **109** (8): 483-92 (2015), PMID: 26085474.
5. K. M. Hastie *et al.*, Structural basis for antibody-mediated neutralization of Lassa virus. *Science* **356**, 923-8 (2017), PMID: 28572385.
6. J. E. Robinson *et al.*, Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. *Nat Commun* **7**, 11544 (2016), PMID: 27161536.
7. M. L. Heinrich *et al.*, Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. *Sci Rep* **10** (1):16030 (2020), PMID: 32994446.
8. L. M. Branco *et al.*, Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report. *Virology* **8**, 404 (2011), PMID: 21843352.
9. L. M. Branco *et al.*, Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. *Virology* **8**, 478 (2011), PMID: 22023795.
10. M. L. Boisen *et al.*, Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. *Viral Immunology* **28**, 19-31 (2015), PMID: 25531344.
11. M. L. Boisen *et al.*, Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. *Sci Rep* **8**, 5939 (2018), PMID: 29651117.
12. M. L. Boisen *et al.*, Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. *Sci Rep* **10**(1): 8724 (2020), PMID: 32457420.
13. J. G. Shaffer *et al.*, Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012-2019. *Microorganisms* **9**(3): 586 (2021), PMID: 33809204.

SYMBOL LEGEND

							
Manufacturer	Batch Code	Use by/ Expiry Date	Temperature Limitations	Irritant	Biological Risk	Catalog Number	Consult Instructions for Use (Package Insert)

WARRANTY

Zalgen Labs, LLC disclaims any implied warranty of merchantability or fitness for a particular use, and in no event shall Zalgen Labs, LLC be liable for consequential damage.

For Technical or Customer Service:

Phone +1 301 720 0330, US Toll Free 1 833 482 8833

Fax +1 301 349 1194

Email admin@zalgenlabs.com



Zalgen Labs, LLC
7495 New Horizon Way, Suite 120
Frederick MD 21703 USA
©2022, Zalgen Labs, LLC

Doc. No.: PI-13MR 01

Effective: 2022-03-02